Paramount’s action comedy Novocaine saw the brilliant Jack Quaid continue his strong 2025 run, following the late-January release of the widely acclaimed sci-fi thriller, Companion. Having just debuted in theaters across the most recent weekend,

March 2025 was never going to be huge at the domestic box office. While this time last year saw the movie release calendar populated with titles including Denis Villeneuve's Dune: Part Two, Mike Mitchell's Kung Fu Panda 4,

Jack Quaid’s action-comedy “Novocaine” topped a painfully slow weekend at the box office with $8.7 million. For theater owners, however, there’s not too much to celebrate: It’s one of the worst debuts to still capture the No.

Novocaine could have been written by a 12-year-old, and I’m not sure I mean that pejoratively. It’s a riff on superhero stories, but it’s been thought up with a whiff of dopey plausibility: The film’s protagonist,

Novocaine hit theaters hard this weekend, and star Jack Quaid caught the eye of an unexpected fandom. As the movie made headlines and the hype reached new heights, many commenters online began to suggest that Quaid could finally bring the Max Payne video game franchise to the big screen.

“Novocaine” only cost $18 million to produce, so (like its main character) it shouldn’t be feeling any pain at the box office. On the flip side, “Mickey 17” cost $118 million to produce and needs around $275 million to $300 million worldwide to make a profit.

Jack Quaid's new action film takes the top spot at the box office, knocking Bong Joon Ho's Mickey 17 into second place.